Kiran K Turaga

List of Publications by Year
in descending order

185 papers	4,610 citations	117625 34 h-index	128289 60 g-index
189 all docs	189 docs citations	189 times ranked	6425 citing authors

#	Article	IF	Citations
1	Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. Cancer Discovery, 2018, 8, 37-48.	9.4	248
2	Pathologic Response after Neoadjuvant Therapy is the Major Determinant of Survival in Patients with Esophageal Cancer. Annals of Surgical Oncology, 2010, 17, 1159-1167.	1.5	205
3	Microwave Ablation for Hepatic Malignancies. Annals of Surgery, 2014, 259, 1195-1200.	4.2	202
4	Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: A Systematic Review and Meta-analysis. Annals of Surgical Oncology, 2015, 22, 1686-1693.	1.5	188
5	Importance of Histologic Subtype in the Staging of Appendiceal Tumors. Annals of Surgical Oncology, 2012, 19, 1379-1385.	1.5	173
6	Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma. Journal of Clinical Oncology, 2018, 36, 2863-2871.	1.6	158
7	Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. Journal of Surgical Oncology, 2015, 111, 213-220.	1.7	146
8	The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis. Annals of Surgical Oncology, 2014, 21, 4195-4201.	1.5	141
9	The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. Journal of Surgical Oncology, 2014, 110, 779-785.	1.7	134
10	Recent progress in the understanding, diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumors. Ca-A Cancer Journal for Clinicians, 2011, 61, 113-132.	329.8	116
11	Repair of 104 Failed Anti-Reflux Operations. Annals of Surgery, 2006, 244, 42-51.	4.2	91
12	Primary and metastatic peritoneal surface malignancies. Nature Reviews Disease Primers, 2021, 7, 91.	30.5	87
13	Chemotherapy for Surgically Resected Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2015, 22, 3716-3723.	1.5	83
14	Systematic review of outcomes of patients undergoing resection for colorectal liver metastases in the setting of extra hepatic disease. European Journal of Cancer, 2014, 50, 1747-1757.	2.8	82
15	Transplantation versus resection for patients with combined hepatocellular carcinomaâ€“cholangiocarcinoma. Journal of Surgical Oncology, 2013, 107, 608-612.	1.7	80
16	Surgical management of hepatic hemangiomas: a multi-institutional experience. Hpb, 2014, 16, 924-928.	0.3	66
17	Are We Harming Cancer Patients by Delaying Their Cancer Surgery During the COVID-19 Pandemic?. Annals of Surgery, 2023, 278, e960-e965.	4.2	65
18	Right Hemicolectomy for Mucinous Adenocarcinoma of the Appendix: Just Right or Too Much?. Annals of Surgical Oncology, 2013, 20, 1063-1067.	1.5	60

#	Article	IF	Citations
19	Role of laparoscopy in patients with peritoneal metastases considered for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). World Journal of Surgical Oncology, 2014, 12, 270.	1.9	59
20	Suicide in patients with pancreatic cancer. Cancer, 2011, 117, 642-647.	4.1	57
21	Chronic Mesenteric Ischemia:Endovascular Versus Open Revascularization. Journal of Endovascular Therapy, 2010, 17, 540-549.	1.5	54
22	Management of Malignant Peritoneal Mesothelioma Using Cytoreductive Surgery and Perioperative Chemotherapy. Journal of Oncology Practice, 2016, 12, 928-935.	2.5	50
23	Surgical management of bowel obstruction in patients with peritoneal carcinomatosis. Journal of Surgical Oncology, 2014, 110, 666-669.	1.7	49
24	Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease. Cancer Discovery, 2021, 11, 308-325.	9.4	49
25	An Elevated Body Mass Index Does Not Reduce Survival After Esophagectomy for Cancer. Annals of Surgical Oncology, 2011, 18, 824-831.	1.5	47
26	Recurrence after microwave ablation of liver malignancies: a single institution experience. Hpb, 2013, 15, 365-371.	0.3	45
27	Comparative Effectiveness of Hepatic Artery Based Therapies for Unresectable Colorectal Liver Metastases: A Meta-Analysis. PLoS ONE, 2015, 10, e0139940.	2.5	43
28	Incorporation of diagnostic laparoscopy in the management algorithm for patients with peritoneal metastases: A multiâ€institutional analysis. Journal of Surgical Oncology, 2015, 111, 1035-1040.	1.7	41
29	Palliative Care Training in Surgical Oncology and Hepatobiliary Fellowships: A National Survey of the Fellows. Annals of Surgical Oncology, 2015, 22, 1761-1767.	1.5	40
30	Assessment of Diaphragmatic Stressors as Risk Factors for Symptomatic Failure of Laparoscopic Nissen Fundoplication. Journal of Gastrointestinal Surgery, 2006, 10, 12-21.	1.7	39
31	Does histology predict outcome for malignant vascular tumors of the liver?. Journal of Surgical Oncology, 2014, 109, 483-486.	1.7	39
32	Limb Preservation With Isolated Limb Infusion for Locally Advanced Nonmelanoma Cutaneous and Soft-Tissue Malignant Neoplasms. Archives of Surgery, 2011, 146, 870.	2.2	38
33	Can We Continue to Ignore Gender Differences in Performance on Simulation Trainers?. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2011, 21, 329-333.	1.0	38
34	Current Trends in the Management of Malignant Peritoneal Mesothelioma. Annals of Surgical Oncology, 2014, 21, 3947-3953.	1.5	38
35	Cost and Morbidity Analysis of Chest Port Insertion: Interventional Radiology Suite Versus Operating Room. Journal of the American College of Radiology, 2015, 12, 563-571.	1.8	38
36	Neutrophilâ€toâ€lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma: A Western perspective. Journal of Surgical Oncology, 2014, 109, 95-97.	1.7	36

#	Article	IF	Citations
37	Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer. JAMA Oncology, 2019, 5, 236.	7.1	36
38	The Chicago Consensus on peritoneal surface malignancies: Management of appendiceal neoplasms. Cancer, 2020, 126, 2525-2533.	4.1	35
39	Measuring the Surgical Academic Output of an Institution: The â€œInstitutionalâ€•H-Index. Journal of Surgical Education, 2012, 69, 499-503.	2.5	34
40	Surgical resection versus ablation for hepatocellular carcinoma â‰¤Â3Âcm: a population-based analysis. Hpb, 2015, 17, 896-901.	0.3	34
41	Is local resection adequate for T1 stage ampullary cancer?. Hpb, 2015, 17, 66-71.	0.3	34
42	Role of Interventional Radiology in the Treatment of Patients with Neuroendocrine Metastases in the Liver. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, 765-772.	4.9	32
43	A literature review of radiological findings to guide the diagnosis of gallbladder adenomyomatosis. Hpb, 2016, 18, 129-135.	0.3	29
44	Evolving Treatment Strategies and Outcomes in Advanced Gastric Cancer with Peritoneal Metastasis. Surgical Oncology Clinics of North America, 2018, 27, 519-537.	1.5	29
45	Retroperitoneal solitary fibrous tumor: surgery as first line therapy. Clinical Sarcoma Research, 2015, 5, 19.	2.3	28
46	Is Radiotherapy Warranted Following Intrahepatic Cholangiocarcinoma Resection? The Impact of Surgical Margins and Lymph Node Status on Survival. Annals of Surgical Oncology, 2016, 23, 912-920.	1.5	28
47	Under-representation of peritoneal metastases in published clinical trials of metastatic colorectal cancer. Lancet Oncology, The, 2017, 18, 711-712.	10.7	28
48	Impact of surgical volume of centers on post-operative outcomes from cytoreductive surgery and hyperthermic intra-peritoneal chemoperfusion. Journal of Gastrointestinal Oncology, 2016, 7, 122-8.	1.4	28
49	Staging chest computed tomography and positron emission tomography in patients with pancreatic adenocarcinoma: utility or futility?. Hpb, 2014, 16, 70-74.	0.3	26
50	Current management strategies for peritoneal mesothelioma. International Journal of Hyperthermia, 2017, 33, 579-581.	2.5	26
51	Discordance of COVIDâ€19 guidelines for patients with cancer: A systematic review. Journal of Surgical Oncology, 2020, 122, 579-593.	1.7	26
52	Evaluation of the Association of Perioperative UGT1A1 Genotypeâ€“Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma. JAMA Network Open, 2020, 3, e1921290.	5.9	26
53	Inguinal Hernias: Should We Repair?. Surgical Clinics of North America, 2008, 88, 127-138.	1.5	25
54	Gene Expression Profiling in Breast Cancer. Cancer Control, 2010, 17, 177-182.	1.8	24

#	Article	IF	Citations
55	Key Factors Influencing Prognosis in Relation to Gallbladder Cancer. Digestive Diseases and Sciences, 2013, 58, 2455-2462.	2.3	24
56	Neoadjuvant radiotherapy for retroperitoneal sarcoma: A systematic review. Journal of Surgical Oncology, 2016, 113, 628-634.	1.7	24
57	Palliative Care Training in Surgical Oncology and Hepatobiliary Fellowships: A National Survey of Program Directors. Annals of Surgical Oncology, 2015, 22, 1181-1186.	1.5	23
58	Peritoneal Metastases in Colorectal Cancer. Annals of Surgical Oncology, 2018, 25, 2145-2151.	1.5	23
59	Cytoreduction and hyperthermic intraperitoneal chemotherapy in metastatic colorectal cancer. Journal of Surgical Oncology, 2019, 119, 613-615.	1.7	23
60	Ablation for Hepatocellular Carcinoma: Validating the 3-cm Breakpoint. Annals of Surgical Oncology, 2013, 20, 3591-3595.	1.5	22
61	Diagnostic laparoscopy should be performed before definitive resection for pancreatic cancer: a financial argument. Hpb, 2015, 17, 131-139.	0.3	22
62	Minimally invasive gastrectomy for cancer: current utilization in US academic medical centers. Surgical Endoscopy and Other Interventional Techniques, 2015, 29, 3768-3775.	2.4	22
63	In hospital outcomes after pancreatectomies: An analysis of a national database from 1996 to 2004. Journal of Surgical Oncology, 2008, 98, 156-160.	1.7	21
64	Obstruction predicts worse long-term outcomes in stage III colon cancer: A secondary analysis of the N0147 trial. Surgery, 2018, 164, 1223-1229.	1.9	21
65	The Chicago Consensus on peritoneal surface malignancies: Management of gastric metastases. Cancer, 2020, 126, 2541-2546.	4.1	21
66	Single-institution Outcome Experience Using AlloDermÂ® as Temporary Coverage or Definitive Reconstruction for Cutaneous and Soft Tissue Malignancy Defects. American Surgeon, 2013, 79, 476-482.	0.8	20
67	Determinants of outcomes in pancreatic surgery and use of hospital resources. Journal of Surgical Oncology, 2011, 104, 634-640.	1.7	19
68	Hyperthermic Intraperitoneal Chemotherapy and Cytoreductive Surgery in the Management of Peritoneal Carcinomatosis. Cancer Control, 2016, 23, 36-46.	1.8	19
69	Cholangitis After Coil Embolization of an Iatrogenic Hepatic Artery Pseudoaneurysm. Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 2006, 16, 36-38.	0.8	18
70	Review of the Impact of Antineoplastic Therapies on the Risk for Cholelithiasis and Acute Cholecystitis. Annals of Surgical Oncology, 2014, 21, 240-247.	1.5	18
71	Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy. British Journal of Cancer, 2021, 124, 564-566.	6.4	18
72	Peritoneal Metastases in Colorectal Cancer: Biology and Barriers. Journal of Gastrointestinal Surgery, 2020, 24, 720-727.	1.7	17

#	Article	IF	Citations
73	The Chicago Consensus on peritoneal surface malignancies: Management of colorectal metastases. Cancer, 2020, 126, 2534-2540.	4.1	17
74	Selective Application of Routine Preoperative Axillary Ultrasonography Reduces Costs for Invasive Breast Cancers. Oncologist, 2011, 16, 942-948.	3.7	16
75	Tumor profiling of gastric and esophageal carcinoma reveal different treatment options. Cancer Biology and Therapy, 2015, 16, 764-769.	3.4	16
76	The Delphi and GRADE methodology used in the PSOGI 2018 consensus statement on Pseudomyxoma Peritonei and Peritoneal Mesothelioma. European Journal of Surgical Oncology, 2021, 47, 4-10.	1.0	16
77	Palliative interventions for hepatocellular carcinoma patients: analysis of the National Cancer Database. Annals of Palliative Medicine, 2017, 6, 26-35.	1.2	15
78	Metastatic Colorectal Cancers with Mismatch Repair Deficiency Result in Worse Survival Regardless of Peritoneal Metastases. Annals of Surgical Oncology, 2020, 27, 5074-5083.	1.5	15
79	The Chicago Consensus on peritoneal surface malignancies: Management of peritoneal mesothelioma. Cancer, 2020, 126, 2547-2552.	4.1	15
80	A (9;11)(q34;q13) translocation in a hibernoma. Cancer Genetics and Cytogenetics, 2006, 170, 163-166.	1.0	14
81	The Frey Procedure for Chronic Pancreatitis Secondary to Pancreas Divisum. JAMA Surgery, 2013, 148, 1057.	4.3	14
82	Management of primary hepatopancreatobiliary small cell carcinoma. Journal of Surgical Oncology, 2013, 107, 692-695.	1.7	14
83	The use of isolated limb infusion in limb threatening extremity sarcomas. International Journal of Hyperthermia, 2013, 29, 1-7.	2.5	14
84	Assessment of the Surgical Workforce Pertaining to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in the United States. Annals of Surgical Oncology, 2020, 27, 3097-3102.	1.5	14
85	Surgical team familiarity and waste generation in the operating room. American Journal of Surgery, 2021, 222, 694-699.	1.8	13
86	The Surgical Treatment of Breast Cancer in the Elderly: A Single Institution Comparative Review of 5235 Patients with 1028 Patients â‰¥70â€ƒyears. Breast Journal, 2012, 18, 428-435.	1.0	12
87	Surgical Resection in Hepatocellular Carcinoma Patients with Minimal Background Fibrosis: A Strategy in the Era of Organ Shortage. Annals of Surgical Oncology, 2013, 20, 2043-2048.	1.5	12
88	Is longâ€term survival possible after marginâ€positive resection of retroperitoneal sarcoma (RPS)?. Journal of Surgical Oncology, 2016, 113, 823-827.	1.7	12
89	ReCAP: Cost Differential of Chemotherapy for Solid Tumors. Journal of Oncology Practice, 2016, 12, 251-251.	2.5	12
90	Facilities that service economically advantaged neighborhoods perform surgical metastasectomy more often for patients with colorectal liver metastases. Cancer, 2020, 126, 281-292.	4.1	12

#	Article	IF	Citations
91	A Multi-institutional Study of Peritoneal Recurrence Following Resection of Low-grade Appendiceal Mucinous Neoplasms. Annals of Surgical Oncology, 2021, 28, 4685-4694.	1.5	12
92	Novel Multimodality Treatment Sequencing for Extrahepatic (Mid and Distal) Cholangiocarcinoma. Annals of Surgical Oncology, 2013, 20, 1230-1239.	1.5	11
93	Defining the Role of Adjuvant External Beam Radiotherapy on Resected Adenocarcinoma of the Ampulla of Vater. Journal of Gastrointestinal Surgery, 2014, 18, 2003-2008.	1.7	11
94	The Chicago Consensus on peritoneal surface malignancies: Management of ovarian neoplasms. Cancer, 2020, 126, 2553-2560.	4.1	11
95	Intrahepatic cholangiocarcinoma and gallbladder cancer: distinguishing molecular profiles to guide potential therapy. Hpb, 2015, 17, 1119-1123.	0.3	10
96	Challenges to clinical utilization of hereditary cancer gene panel testing: perspectives from the front lines. Familial Cancer, 2015, 14, 641-649.	1.9	10
97	Morbidity of curative cancer surgery and suicide risk. Psycho-Oncology, 2017, 26, 1792-1798.	2.3	10
98	Inguinal hernia repair in a developing country. Hernia: the Journal of Hernias and Abdominal Wall Surgery, 2006, 10, 294-298.	2.0	9
99	Management of acute cholecystitis in cancer patients: a comparative effectiveness approach. Surgical Endoscopy and Other Interventional Techniques, 2014, 28, 1505-1514.	2.4	9
100	Immunohistochemistry Ã¢â‚¬â€œ Microarray Analysis of Patients with Peritoneal Metastases of Appendiceal or Colorectal Origin. Frontiers in Surgery, 2014, 1, 50.	1.4	9
101	Factors associated with palliative care use in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Journal of Surgical Research, 2017, 211, 79-86.	1.6	9
102	The Chicago Consensus on peritoneal surface malignancies: Methodology. Cancer, 2020, 126, 2513-2515.	4.1	9
103	Mismatch Repair Status Correlates with Survival in Young Adults with Metastatic Colorectal Cancer. Journal of Surgical Research, 2021, 266, 104-112.	1.6	9
104	Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Technical considerations and the learning curve. Journal of Surgical Oncology, 2020, 122, 85-95.	1.7	9
105	Does laparoscopic surgery decrease the risk of atrial fibrillation after foregut surgery?. Surgical Endoscopy and Other Interventional Techniques, 2009, 23, 204-208.	2.4	8
106	Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma: Improvements Needed in Population-Based Registries. Annals of Surgical Oncology, 2013, 20, 4338-4347.	1.5	8
107	Molecular profiling in gastric cancer: Examining potential targets for chemotherapy. Journal of Surgical Oncology, 2014, 110, 302-306.	1.7	8
108	Differences in Sociodemographic Disparities Between Patients Undergoing Surgery for Advanced Colorectal or Ovarian Cancer. Annals of Surgical Oncology, 2021, 28, 7795-7806.	1.5	8

#	Article	IF	Citations
109	Guide to Enhanced Recovery for Cancer Patients Undergoing Surgery: ERAS for Patients Undergoing Cytoreductive Surgery with or Without HIPEC. Annals of Surgical Oncology, 2021, 28, 6955-6964.	1.5	8
110	Neoadjuvant therapy for pancreatic cancer in patients older than age 75.. Journal of Clinical Oncology, 2014, 32, 287-287.	1.6	8
111	A Meta-analysis of Randomized Controlled Trials in Critically Ill Patients to Evaluate the Dose-Response Effect of Erythropoietin. Journal of Intensive Care Medicine, 2007, 22, 270-282.	2.8	7
112	Attributes of a surgical chairperson associated with extramural funding of a department of surgery. Journal of Surgical Research, 2013, 185, 549-554.	1.6	7
113	Screening Young Adults for Nonhereditary Colorectal Cancer. JAMA Surgery, 2015, 150, 22.	4.3	7
114	The Chicago Consensus on peritoneal surface malignancies: Standards. Cancer, 2020, 126, 2516-2524.	4.1	7
115	Hernia Uterus Inguinale. Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 2006, 16, 366-367.	0.8	6
116	Estimating Surgical Risk for Patients With Severe Comorbidities. JAMA Surgery, 2018, 153, 778.	4.3	6
117	Complete Response in a Patient With Chemorefractory EGFR-Amplified, PD-L1â€“Positive Metastatic Gastric Cancer Treated By Dual Anti-EGFR and Antiâ€“PD-1 Monoclonal Antibody Therapy. JCO Precision Oncology, 2020, 4, 1180-1186.	3.0	6
118	Are We Ready for Hyperthermic Intraperitoneal Chemotherapy in the Upfront Treatment of Ovarian Cancer?. JAMA Network Open, 2020, 3, e2014184.	5.9	6
119	Surgical Treatment of Peritoneal Carcinomatosis from Gastric Cancer. International Journal of Surgical Oncology, 2012, 2012, 1-4.	0.6	5
120	K-Ras and MSI: Potential Markers of Both Patient Prognosis and Treatment Efficacy. Annals of Surgical Oncology, 2010, 17, 354-355.	1.5	4
121	Cost Effectiveness of Routine Laparoscopic Ultrasound for Assessment of Resectability of Gallbladder Cancer. Annals of Surgical Oncology, 2014, 21, 2413-2419.	1.5	4
122	Conditional Survival as a Patient Centered Metric for Patients with Appendiceal Adenocarcinoma. Annals of Surgical Oncology, 2016, 23, 2295-2301.	1.5	4
123	Benchmarking Perioperative Outcomes of Cytoreductive Surgery for Cancer: Implications for Quality Measurement. Annals of Surgical Oncology, 2020, 27, 5039-5046.	1.5	4
124	The Chicago Consensus on peritoneal surface malignancies: Palliative care considerations. Cancer, 2020, 126, 2571-2576.	4.1	4
125	The Chicago Consensus on peritoneal surface malignancies: Management of desmoplastic small round cell tumor, breast, and gastrointestinal stromal tumors. Cancer, 2020, 126, 2566-2570.	4.1	4
126	Novel Application of Iterative Hyperthermic Intraperitoneal Chemotherapy for Unresectable Peritoneal Metastases from High-Grade Appendiceal Ex-Goblet Adenocarcinoma. Annals of Surgical Oncology, 2021, 28, 1777-1785.	1.5	4

#	Article	IF	Citations
127	Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage III Melanoma in Medicare Patients. Annals of Surgical Oncology, 2021, 28, 9039-9047.	1.5	4
128	Cytoreductive Surgery for Selected Patients Whose Metastatic Gastric Cancer was Treated with Systemic Chemotherapy. Annals of Surgical Oncology, 2021, 28, 4433-4443.	1.5	4
129	Utility of Perioperative Measurement of Cell-Free DNA and Circulating Tumor DNA in Informing the Prognosis of GI Cancers: A Systematic Review. JCO Precision Oncology, 2022, 6, e2100337.	3.0	4
130	The role of imaging in diagnosis and management of malignant peritoneal mesothelioma: a systematic review. Abdominal Radiology, 2022, 47, 1725-1740.	2.1	4
131	Viral status at the time of liver transplantation for hepatocellular carcinoma: a modern predictor of longterm survival. Hpb, 2013, 15, 794-802.	0.3	3
132	Effect of the experience of surgical chairpersons on departmental National Institutes of Health funding. Journal of Surgical Research, 2014, 192, 293-297.	1.6	3
133	Modern Surgical Techniques in Cytoreductive Surgery. Journal of Gastrointestinal Surgery, 2020, 24, 454-459.	1.7	3
134	HIPEC with cisplatin in a patient with a prior hypersensitivity reaction to systemic oxaliplatin. Basic and Clinical Pharmacology and Toxicology, 2020, 127, 551-553.	2.5	3
135	The Chicago Consensus Guidelines for peritoneal surface malignancies: Introduction. Cancer, 2020, 126, 2510-2512.	4.1	3
136	Personalized ANtibodies for GastroEsophageal Adenocarcinoma (PANGEA): Primary efficacy analysis of the phase II platform trial (NCT02213289).. Journal of Clinical Oncology, 2020, 38, 356-356.	1.6	3
137	Role of Chemotherapy in Peritoneal Carcinomatosis in Metastatic Colorectal Cancer. Current Colorectal Cancer Reports, 2013, 9, 242-249.	0.5	2
138	Age-based disparities in treatment and outcomes of retroperitoneal rhabdomyosarcoma. International Journal of Clinical Oncology, 2016, 21, 602-608.	2.2	2
139	Defining and Refining the Role for Surgery and Intraperitoneal Chemotherapy in the Treatment of Peritoneal Surface Malignancies. Annals of Surgical Oncology, 2020, 27, 73-75.	1.5	2
140	The Chicago Consensus on peritoneal surface malignancies: Management of neuroendocrine tumors. Cancer, 2020, 126, 2561-2565.	4.1	2
141	What should doctors wear?. BMJ: British Medical Journal, 2008, 337, a938-a938.	2.3	2
142	Potential evidence of peritoneal recurrence in Stage-II colon cancer from the control arm of CALGB9581. American Journal of Surgery, 2022, 224, 459-464.	1.8	2
143	A Long-Term Comparison of Plication Configurations for Endoluminal Gastroplication. Journal of Clinical Gastroenterology, 2005, 39, 869-876.	2.2	1
144	Pancreatic Duct Transection: Diagnosis and Management. Journal of Trauma, 2010, 68, E39-E41.	2.3	1

#	Article	IF	Citations
145	Hepatic Perfusion Therapy. Surgical Clinics of North America, 2016, 96, 357-368.	1.5	1
146	Implementation of bundled care to reduce surgical site infections after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Journal of Surgical Oncology, 2019, 120, 1044-1045.	1.7	1
147	ASO Visual Abstract: Differences in Sociodemographic Disparities in Patients Undergoing Surgery for Advanced Colorectal and Ovarian Cancer. Annals of Surgical Oncology, 2021, 28, 430-431.	1.5	1
148	Current Indications for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastrointestinal Malignancies. Advances in Oncology, 2021, 1, 49-61.	0.2	1
149	Perioperative (P) UGT1A1 genotype guided irinotecan (iri) dosing â€˜gFOLFIRINOXâ€™ for gastroesophageal adenocarcinoma (GEA).. Journal of Clinical Oncology, 2019, 37, 4050-4050.	1.6	1
150	Peritoneal Perfusion Techniques. , 2020, , 199-211.		1
151	Multimodal Therapy Including Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Can Result in Long-term Disease-free Survival in Pediatric Desmoplastic Small Round Cell Tumor With Extraperitoneal Disease. Journal of Pediatric Hematology/Oncology, 2021, 43, 228-231.	0.6	1
152	Correlation of circulating tumor DNA (ctDNA) with clinical outcomes in appendiceal cancers (AC).. Journal of Clinical Oncology, 2022, 40, 29-29.	1.6	1
153	Impact of hyperthermic intraperitoneal chemotherapy on genomic heterogeneity of peritoneal metastases in stage IV gastroesophageal adenocarcinoma.. Journal of Clinical Oncology, 2022, 40, 312-312.	1.6	1
154	The Role of Surgery in Managing Primary and Metastatic Colorectal Cancer. , 2022, , 407-419.		1
155	Moving Fast and Moving Slow. Annals of Surgical Oncology, 2015, 22, 1631-1633.	1.5	0
156	Regional Therapies for Advanced Cancer: Update for 2016. Annals of Surgical Oncology, 2016, 23, 1452-1453.	1.5	0
157	Ushering in a New Era for Regional Therapies. Annals of Surgical Oncology, 2017, 24, 868-869.	1.5	0
158	Registries and Collaborative Groups in Peritoneal Surface Oncology. , 2018, , 507-526.		0
159	Together We Make a Difference. Annals of Surgical Oncology, 2018, 25, 1794-1796.	1.5	0
160	Malignant Peritoneal Mesothelioma. , 2018, , 361-368.		0
161	It Is Time. Annals of Surgical Oncology, 2019, 26, 1963-1966.	1.5	0
162	Gastric volvulus involving the duodenum. BMJ Case Reports, 2019, 12, e229930.	0.5	0

#	Article	IF	Citations
163	ASO Visual Abstract: Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage 3 Melanoma in Medicare Patients. Annals of Surgical Oncology, 2021, 28, 576-576.	1.5	0
164	Does a common vascular origin confer similar prognosis to malignant tumors of the liver?. Journal of Clinical Oncology, 2012, 30, 186-186.	1.6	0
165	Is survival from resection of pancreatic adenocarcinoma with major arterial involvement any different than venous/minor arterial resection?. Journal of Clinical Oncology, 2012, 30, 310-310.	1.6	0
166	Are we justified in excluding combined hepatocellular-cholangiocarcinoma from transplantation?. Journal of Clinical Oncology, 2012, 30, 256-256.	1.6	0
167	Analysis of toxicity and outcomes in patients undergoing hyperthermic isolated hepatic perfusion with melphalan for metastatic melanoma to the liver.. Journal of Clinical Oncology, 2013, 31, 178-178.	1.6	0
168	Ablation for hepatocellular carcinoma: Validating the 3-cm breakpoint.. Journal of Clinical Oncology, 2013, 31, 277-277.	1.6	0
169	Molecular profiling in gastric cancer: Examining potential targets for chemotherapy.. Journal of Clinical Oncology, 2014, 32, 131-131.	1.6	0
170	Cost-effectiveness of routine laparoscopic ultrasound for the assessment of resectability of gallbladder cancer.. Journal of Clinical Oncology, 2014, 32, 272-272.	1.6	0
171	Cost differential among systemic therapies for colon cancer.. Journal of Clinical Oncology, 2014, 32, 583-583.	1.6	0
172	Tumor profiling of 1,306 gastric and esophageal carcinomas and different treatment options.. Journal of Clinical Oncology, 2014, 32, 4017-4017.	1.6	0
173	Cost differential among systemic therapies for breast, bladder, lung, and colon cancer.. Journal of Clinical Oncology, 2014, 32, e17541-e17541.	1.6	0
174	Chemotherapy for surgically resected intrahepatic cholangiocarcinoma: Influence of lymph node status on treatment efficacy.. Journal of Clinical Oncology, 2015, 33, 353-353.	1.6	0
175	Conditional probability of survival in gallbladder carcinoma as a prognostic tool for long term survivors.. Journal of Clinical Oncology, 2016, 34, 455-455.	1.6	0
176	Palliative care for hepatocellular carcinoma: Analysis of the National Cancer Data Base.. Journal of Clinical Oncology, 2016, 34, 390-390.	1.6	0
177	Chasing the proverbial unicorn of relative value units (RVU) and block time.. Journal of Clinical Oncology, 2016, 34, 660-660.	1.6	0
178	Overall survival and resection margin after hepatectomy for intrahepatic cholangiocarcinoma at academic cancer centers versus community cancer centers.. Journal of Clinical Oncology, 2016, 34, 339-339.	1.6	0
179	Conversion to resectability in unresectable metastatic colorectal cancer chemotherapy (mCRC) trials.. Journal of Clinical Oncology, 2016, 34, 641-641.	1.6	0
180	Radiotherapy for intrahepatic cholangiocarcinoma: An analysis of the National Cancer Database.. Journal of Clinical Oncology, 2016, 34, 379-379.	1.6	0

#	Article	IF	Citations
181	Implementation of an EMR integrated pathway for the management of malignant bowel obstruction.. Journal of Clinical Oncology, 2020, 38, 813-813.	1.6	0
182	Cytoreductive surgery in selected patients with metastatic gastric cancer treated with systemic chemotherapy.. Journal of Clinical Oncology, 2020, 38, 409-409.	1.6	0
183	5-hydroxymethylation signatures in plasma circulating cell-free DNA as markers for appendiceal and colorectal peritoneal metastasis.. Journal of Clinical Oncology, 2020, 38, 195-195.	1.6	0
184	Survival in total preoperative verus perioperative chemotherapy for patients with metastatic high-grade appendiceal adenocarcinoma undergoing CRS/HIPEC.. Journal of Clinical Oncology, 2022, 40, 90-90.	1.6	0
185	Utilization of nano-hmC-seal technology to detect epigenetic signatures of peritoneal metastasis in cell-free DNA (cfDNA) in patients with colorectal and high-grade appendiceal cancer.. Journal of Clinical Oncology, 2022, 40, e15510-e15510.	1.6	0